The global companion animal cardiac drugsmarket size was valued at USD 2.24 billion in 2025 and is projected to grow from USD 2.423 billion in 2026 to USD 4.71 billion by 2034, registering a CAGR of 8.60% during the forecast period (2026-2034). North America dominated the companion animal cardiac drugs market with a share of 42.1% in 2025.
Companion animal cardiac drugs are veterinary pharmaceutical products designed to manage cardiovascular conditions in pets, primarily dogs and cats. They are generally classified under HSN Code 3004 (medicaments for therapeutic or prophylactic uses), while SIC Code 2834 covers pharmaceutical preparations.
The companion animal cardiac drug market demand is driven by the prevalence of cardiovascular disorders in pets, the expansion of advanced veterinary healthcare services, and a focus on long-term cardiac disease management. Veterinary healthcare providers are adopting cardiac medications such as pimobendan, diuretics, and ACE inhibitors, contributing to companion animal cardiac drug market growth.
Download a Free Sample To learn more about this report,
Innovations in Long-Acting Cardiac Drug Formulations
The companion animal cardiac drugs market analysis shows that veterinary pharmaceutical developers are exploring long-acting cardiac drug formulations. This encourages companies to develop controlled-release technologies that maintain therapeutic effects over extended periods and simplify the management of chronic cardiovascular conditions in companion animals. This transition is shifting veterinary cardiac treatment toward sustained drug delivery and more convenient long-term medication approaches.
Development of Novel Therapies for Feline Cardiomyopathy
The companion animal cardiac drugs market is seeing a shift toward specialized treatments for feline cardiovascular conditions, particularly hypertrophic cardiomyopathy, which causes thickening of the heart muscle. This transition is encouraging veterinary pharmaceutical developers to explore targeted therapies that manage structural changes in the heart before severe clinical symptoms develop. For example, Felycin-CA1, a sirolimus-based delayed-release tablet developed for cats with subclinical hypertrophic cardiomyopathy, introduces a once-weekly treatment approach for managing ventricular hypertrophy and reflects the evolution of condition-specific therapies in veterinary cardiology.
Supply chain disruptions are expected to have a moderate impact on the companion animal cardiac drugs market share due to dependence on active pharmaceutical ingredients, specialized formulations, drug packaging materials, and transportation networks. The market is likely to follow an S-shaped recovery, with gradual restoration of raw material supplies and manufacturing operations. Supply chain constraints could reduce market growth by 1.0–1.5 percentage points, lowering the projected CAGR of 8.60% to around 7.10%–7.60%. As supply conditions normalize through diversified sourcing and smoother distribution, the companion animal cardiac drugs market growth is expected to stabilize.
The companion animal cardiac drugs market forecasts strategic investment activity driven by advancements in veterinary therapeutics and development of innovative cardiac medications. In June 2026, Rejuvenate Bio secured USD 6 million in financing led by VCapital, with participation from Merck Animal Health, Connecticut Innovations, and Digitalis. The funding supports its gene therapy platform and pipeline for chronic and age-associated diseases in companion animals.
Increasing Prevalence of Myxomatous Mitral Valve Disease in Dogs and Demand for Early Cardiac Diagnosis in Pets Drive Market
Myxomatous mitral valve disease (MMVD) is a leading cardiac condition in dogs, accounting for approximately 75% of canine heart disease cases seen in veterinary practices across North America. The condition is particularly common among older and small-breed dogs, including Cavalier King Charles Spaniels, creating demand for cardiac medications and long-term disease management. Consequently, veterinary cardiologists prescribe treatments such as pimobendan and diuretics to manage disease progression and associated heart failure.
Emphasis on early identification of cardiac abnormalities is encouraging regular veterinary examinations and diagnostic monitoring in predisposed dog breeds. The American College of Veterinary Internal Medicine recommends regular veterinary evaluations for small-breed dogs at risk of MMVD, supporting the use of auscultation and, when indicated, echocardiography and radiography to assess disease progression.
High expenses associated with cardiac medications, veterinary consultations, diagnostic tests, and long-term monitoring increase the financial burden of treating companion animals. These costs lead pet owners to delay treatment, reduce medication adherence, or avoid regular follow-up care. Affordability challenges limit the adoption of companion animal cardiac drugs and affect treatment continuity.
Limited access to veterinary cardiology specialists and advanced diagnostic facilities delays the identification and management of cardiac conditions in dogs and cats. General veterinary clinics may have fewer resources for specialized cardiac assessments and complex treatment decisions, particularly in underserved regions.
Development of Species-Specific Cardiac Therapies and Novel Treatment Options Offers Growth Opportunities to Market Players
Need for targeted treatments for canine and feline cardiovascular conditions creates opportunities for veterinary pharmaceutical companies to develop therapies for specific diseases and unmet treatment needs. These innovations help manufacturers expand their product portfolios and reach specialized veterinary cardiology segments. For example, TriviumVet’s Felycin-CA1, a sirolimus delayed-release tablet conditionally approved in the U.S. for managing feline hypertrophic cardiomyopathy, represents a specialized treatment approach for cat heart disease.
Convenient and consistent medication administration in pets creates opportunities for veterinary pharmaceutical companies to develop advanced drug delivery systems, including sustained-release formulations and easier-to-administer dosage forms. These innovations help manufacturers differentiate their cardiac drug portfolios and address treatment adherence challenges among pet owners. Companies investing in formulation development expand their product offerings and generate additional revenue by meeting the long-term treatment needs of dogs and cats.
Pimobendan accounted for a share of 42.5% in 2025, owing to its established use in managing congestive heart failure in dogs and improving cardiac function. Widespread adoption of pimobendan-based treatments by veterinary practitioners supports demand for cardiac medications, strengthening the segment's position in the companion animal cardiac drug market.
The spironolactone and benazepril segment is anticipated to record a growth rate of 8.8% during the forecast period, driven by the demand for effective heart failure management, wider use of combination drug therapies in veterinary practice, and the need for long-term treatment of cardiovascular conditions in companion animals.
Request Customizationto receive a tailored report.
Dogs dominated the animal type segment with a share of 68.5% in 2025 due to the widespread use of cardiac medications to manage canine cardiovascular conditions, including congestive heart failure and dilated cardiomyopathy.
Cats are projected to undergo growth at a CAGR of 9.8% during the forecast period, fueled by increasing awareness of feline heart conditions, including hypertrophic cardiomyopathy, and the rising demand for specialized veterinary cardiac treatments. The emphasis on early diagnosis and long-term management of feline cardiovascular diseases also support the adoption of cardiac medications for cats.
In 2025, hospitals and clinic pharmacies led the distribution channel segment with a share of 57.8%. This dominance is led by the direct availability of prescribed cardiac medications and the need for veterinarian-guided treatment of cardiovascular conditions in companion animals.
Retail pharmacies are likely to witness a CAGR of 8.3% during the forecast period, supported by the availability of veterinary cardiac medications and convenient access to prescribed treatments. The demand for long-term medication management among pet owners is expected to support retail pharmacy sales of companion animal cardiac drugs.
Speak to an Analystto discuss market opportunities.
The North America companion animal cardiac drug market accounted for a dominant share of 42.1% in 2025.
U.S. Food and Drug Administration (FDA) requires veterinary drugs, including companion animal cardiac medications, to meet applicable standards for safety, efficacy, and quality before approval and marketing. These requirements encourage manufacturers to develop improved cardiac formulations and advance treatments for canine and feline heart conditions, including heart failure, arrhythmias, and other cardiovascular diseases.
According to Agriculture and Agri-Food Canada, Canada had 17.3 million dogs and cats in 2025, reflecting a substantial population of companion animals requiring veterinary healthcare. Thus, the need for diagnosis and long-term management of canine and feline heart conditions supports demand for companion animal cardiac drugs in Canada.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific companion animal cardiac drugs market will expand at a CAGR of 7.68%, showcasing the fastest-growing regional market.
Japan’s Ministry of Agriculture, Forestry and Fisheries (MAFF) supports veterinary vaccine development and regulatory oversight through its animal health policies and initiatives. These efforts encourage vaccine innovation, improved formulations, and the development of products targeting canine and feline infectious diseases, supporting the adoption of advanced companion animal vaccines in Japan.
The Chinese market is supported by rising pet ownership, increasing expenditure on veterinary healthcare, and growing awareness of preventive vaccination among pet owners. Investments in veterinary healthcare infrastructure and the expansion of animal health services improve access to routine immunization. These developments continue to strengthen demand for dog vaccines, cat vaccines, and other veterinary pharmaceuticals in China.
The Department of Animal Husbandry and Dairying introduced Pashu Aushadhi, a programme for distributing affordable generic veterinary medicines through selected Pradhan Mantri Kisan Samriddhi Kendras and cooperative societies. The government identified 134 generic veterinary medicines and related consumables for procurement. This initiative provides a distribution model that can improve access to veterinary medicines, while demand for treatments such as pimobendan for canine congestive heart failure supports the need for specialised companion-animal cardiac drugs.
Europe's companion animal cardiac drugs market is anticipated to grow at a CAGR of 8.1% during the forecast period.
Research by the Royal Veterinary College has demonstrated the benefits of pimobendan in delaying the onset of congestive heart failure in dogs with preclinical degenerative mitral valve disease. These findings support evidence-based treatment practices and demand for cardiac medications for long-term cardiovascular disease management.
European Medicines Agency authorises veterinary cardiac medicines such as Cardalis, containing benazepril and spironolactone, and Vetmedin, containing pimobendan, for relevant canine cardiac conditions. This established treatment landscape supports demand for cardiac drugs that help manage heart failure and improve long-term disease control in companion animals. The EU Veterinary Medicines Information database lists generic benazepril tablets authorised in Germany, alongside combination therapies such as Cardalis, which contains benazepril and spironolactone.
The Latin America companion animal cardiac drugs market is projected to grow at a CAGR of 9.2% during the forecast period. Brazil’s Ministry of Agriculture and Livestock opened a public consultation on regulations for registering generic and interchangeable veterinary medicines, while a bill introduced in September 2026 proposed incentives for their production and sale.
Mexico’s National Service for Agrifood Health, Safety and Quality (SENASICA) updated its veterinary product regulation information, including registration and authorisation processes for animal-use pharmaceuticals. Across both markets, the expansion of veterinary diagnostic services and greater attention to long-term management of companion animal heart conditions support market development.
The Middle East & Africa companion animal cardiac drugs market is anticipated to grow at a CAGR of 8.9% during the forecast period. UAE’s Federal Decree-Law No. 21 of 2025, effective January 2026, governs the registration, approval, manufacturing, marketing and distribution of veterinary medical products. This framework supports the supply of authorised cardiac medicines for dogs and cats, including treatments for congestive heart failure and other cardiovascular conditions.
South African Health Products Regulatory Authority (SAHPRA) issued an advisory reinforcing compliance with national requirements for veterinary medicines, including the risks associated with unregistered products. This regulatory focus supports demand for registered cardiac medicines used to manage canine congestive heart failure.
The companion animal cardiac drug market competitive landscape is competitive, with established veterinary pharmaceutical companies and animal health product developers. Key players such as Boehringer Ingelheim, Ceva Santé Animale, Elanco Animal Health, Dechra Pharmaceuticals, and Vetoquinol are estimated to account for 35-45% of the global companion animal cardiac drug market share.
Established players compete mainly through treatment effectiveness, product safety, veterinary approval and distribution networks. Regional players in companion animal cardiac drug ecosystem focus on specialized cardiac treatments, affordable veterinary medicines, and therapies for heart conditions in dogs and cats.
June 2026: Cronus Pharma launched generic pimobendan chewable tablets in the U.S. veterinary market for managing congestive heart failure in dogs associated with myxomatous mitral valve disease or dilated cardiomyopathy.
April 2026: Ceva Santé Animale received U.S. FDA approval for Amodip (amlodipine besylate) chewable tablets to control systemic hypertension in cats.
December 2025: Boehringer Ingelheim received full U.S. FDA approval for Vetmedin (pimobendan) chewable tablets to delay the onset of congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Companion Animal Vaccines Market Size, Forecast, Demand, 2034
Animal Sedative Market Size, Forecast, Demand, Opportunities, 2034
Animal Wound Care Market Size, Forecast, Opportunities, 2034
Companion Animal Healthcare Market Size, Share, 2034
Animal Microchip Implant Market Size, Share, Growth, 2034
Pet Care Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com